Navigation Links
New 2009 Cumulative Supplement to Pharmaceutical Patent Law Examines Critical Intersection Of Patent Law and Food And Drug Law
Date:10/14/2009

ARLINGTON, Va., Oct. 14 /PRNewswire-USNewswire/ -- The 2009 Cumulative Supplement to Pharmaceutical Patent Law delivers the latest legal developments in pharmaceutical patent law. Published by BNA Books, a division of BNA, Pharmaceutical Patent Law is supplemented annually and provides complete coverage of intricate topics, including the antitrust implications of patent settlements; the experimental use privilege; and international aspects of the field, including comparative data protection laws, the benefits and limitations of the Paris Convention, the Patent Cooperation Treaty, Foreign Filing Licenses, regional agreements, and the TRIPS agreement.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090529/DC24463LOGO )

The 2009 Cumulative Supplement includes the following new information:

  • Legislative developments in the 111th Congress concerning patents, follow-on biologics, and Hatch-Waxman reform
  • The continuing impact of Supreme Court precedent upon pharmaceutical patent law, including the law of obviousness and declaratory judgment jurisdiction
  • The new rules concerning the extension of the Hatch-Waxman Act's 30-month stay of marketing approval
  • Coverage of judicial reaction to concerns over baseless Paragraph IV ANDA filings
  • Updated information on the construction of pharmaceutical patent claims

Pharmaceutical Patent Law not only reviews current issues of importance, but identifies topics such as parallel importation and authorized generics that are likely to be of growing significance. The treatise is invaluable to the busy practitioner who must keep on track in this evolving area of the law. The author, Professor John R. Thomas, is a member of the faculty of Georgetown University Law Center, Washington, DC, where he teaches courses in both patent and food and drug law. A widely published author in the field of pharmaceutical patent law, he frequently serves as a Special Master in patent litigation before the federal courts.

BNA is a leading private publisher of news and information products for professionals in law and business. In addition to Pharmaceutical Patent Law, BNA's Book Division publishes Biotechnology and the Federal Circuit; Drafting Patent License Agreements; Electronic and Software Patents: Law and Practice; Intellectual Property Taxation: Transaction and Litigation Issues; International Patent Litigation: A Country-by-Country Analysis; Patent Infringement Remedies; Patent Law and Practice; Patent Prosecution: Law, Practice, and Procedure; Patent, Trademark, and Copyright Laws; Patent, Trademark, and Copyright Regulations; Patents and the Federal Circuit; Pharmaceutical Patent Law; Harmon on Patents: Black-Letter Law and Commentary; and other titles in legal specialties. The BNA Books website, including an online catalog, can be found at bnabooks.com.

The new 2009 Cumulative Supplement to Pharmaceutical Patent Law may be purchased alone (Order #1824-PRY9/$225.00 plus tax, shipping, and handling) or with the main volume (Order #9824-PRY9/$390.00 plus tax, shipping, and handling) from BNA Books, PO Box 7814, Edison, NJ 08818-7814. Telephone orders: 1-800-960-1220. Fax orders: 1-732-346-1624. For a free BNA Books catalog, call 1-800-960-1220 or send an e-mail request to books@bna.com. A 10% discount is available on print copies of books when ordered from the website at bnabooks.com. (Please note that discounts cannot be combined).

SOURCE BNA Books


'/>"/>
SOURCE BNA Books
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. PartnerRe Declares Dividends on Series C Cumulative Redeemable Preferred Shares and Series D Cumulative Redeemable Preferred Shares and Corrects Ex-Dividend Trading Date for Common Shares
2. Cumulative radiation exposure shows increased cancer risk for emergency department patients
3. EPA should pursue cumulative risk assessment of phthalates and other chemicals
4. Antioxidant Supplements May Raise Womens Skin Cancer Risk
5. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
6. LifeQuest World Corporation Proud Contributor to Dietary Supplement Education Alliance (DSEA)
7. Vitamin D Supplements May Lengthen Life
8. American Heart Association Surgical Supplement Journal Report: Appropriate Hospital Discharge System Can Prevent Future Cardiac Events
9. U of M study: Health food supplement may curb addiction of pathological gamblers
10. Joint Juice Launches New Ready-to-Drink Glucosamine & Vitamin-Enhanced Dietary Supplement Water Nationwide
11. Wellcorps International Unveils New Nutritional Supplements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... ... June 20, 2017 , ... TwelveStone Health Partners, ... a Nashville-based private equity firm, has invested $3.35 million in the company. ... and Claritas Capital offers the smart money, speed to market and accountability we ...
(Date:6/20/2017)... ... June 20, 2017 , ... United Benefit Advisors ... annual “UBBIE” Awards (pronounced you-bee) for 2017. The award honors Partner Firms, ... involvement with UBA, the clients they serve, and the benefits insurance industry as ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... curriculum , is pleased to announce a new online course entitled Personal ... provides practical insights and evidence-based strategies for achieving optimal well-being and teaches students ...
(Date:6/20/2017)... , ... June 20, 2017 , ... Fresenius Vascular Care, ... minimally invasive techniques to treat and manage a wide range of vascular conditions, has ... initiative. With more than 65 centers represented by more than 40 local brands, a ...
(Date:6/20/2017)... ... 2017 , ... EdChoice and the American Enterprise Institute each ... economic development in economically distressed urban areas. The first report presents a case ... the economic development of the city of Santa Ana, California. The second report ...
Breaking Medicine News(10 mins):
(Date:6/16/2017)... Datascope Corp. is voluntarily performing a worldwide field correction of ... test failure code.     ... PART NUMBER ... 0998-UC-0446HXX; 0998-UC-0479HXX 0998-00-3013-XX;  0998-UC-3013-XX ... This field correction also applies to ...
(Date:6/13/2017)... , June 13, 2017 Zimmer Biomet Holdings, Inc. ... today announced that the U.S. Food and Drug Administration (FDA) ... 3, 2015 relating to its Zhejiang, China ... "The successful clearance of the Warning Letter ... manufacturing facility is a measure of the progress we have ...
(Date:6/9/2017)... INDIANAPOLIS , June 9, 2017 More ... a further effort to help spread lessons learned from ... the International Diabetes Federation (IDF) and Eli Lilly and ... for the second phase of the Bringing Research in ... reaffirming their commitment to helping people with diabetes effectively ...
Breaking Medicine Technology: